Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

被引：12

作者：

Bannerji, Rajat ^{[1
]}

Brown, Jennifer R. ^{[2
]}

Advani, Ranjana H. ^{[3
]}

Arnason, Jon ^{[4
]}

O'Brien, Susan M. ^{[5
]}

Allan, John N. ^{[6
]}

Chavez, Julio C. ^{[7
]}

Barnes, Jeffrey A. ^{[8
]}

Joyce, Robin ^{[4
]}

Ansell, Stephen ^{[9
]}

Topp, Max S. ^{[10
]}

Adriaens, Lieve ^{[11
]}

Ufkin, Melanie ^{[11
]}

Kostic, Ana ^{[11
]}

Paccaly, Anne ^{[11
]}

Gao, Bo ^{[11
]}

Trail, Pamela A. ^{[11
]}

Lowy, Israel ^{[11
]}

Brownstein, Carrie ^{[11
]}

机构：

[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[3] Standford Univ Med Ctr, Stanford Canc Inst, Stanford, CA USA

[4] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA

[5] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA

[6] Weill Cornell Med, Dept Hematol & Oncol, New York, NY USA

[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[8] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Wurzburg, Medizin Klin & Poliklinik 2, Wurzburg, Germany

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

关键词：

D O I：

10.1182/blood.V128.22.621.621

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

621

引用

页数：6